Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
GLYC

GLYC - GlycoMimetics Inc Stock Price, Fair Value and News

0.27USD+0.01 (+3.85%)Market Closed

Market Summary

GLYC
USD0.27+0.01
Market Closed
3.85%

GLYC Stock Price

View Fullscreen

GLYC RSI Chart

GLYC Valuation

Market Cap

16.8M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

1.7K

EV/EBITDA

-2.92

Price/Free Cashflow

-0.5

GLYC Price/Sales (Trailing)

GLYC Profitability

EBT Margin

45954.78%

Return on Equity

-128.94%

Return on Assets

-108.98%

Free Cashflow Yield

-201.83%

GLYC Fundamentals

GLYC Revenue

Revenue (TTM)

10.0K

GLYC Earnings

Earnings (TTM)

-37.3M

Earnings Growth (Yr)

-3.64%

Earnings Growth (Qtr)

-18.26%

Breaking Down GLYC Revenue

Last 7 days

-3.7%

Last 90 days

-90.0%

Trailing 12 Months

-85.4%

How does GLYC drawdown profile look like?

GLYC Financial Health

Current Ratio

6.28

GLYC Investor Care

Shares Dilution (1Y)

0.34%

Diluted EPS (TTM)

-0.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202300010.0K
20220179.3K179.2K92.6K
20212.2M2.2M1.3M1.2M
202029.1M9.0M10.0M10.2M
2015035.1M20.0M20.1M
201406.8M12.3M15.0M
201312.4M9.6M6.8M4.0M
201200015.3M

Tracking the Latest Insider Buys and Sells of GlycoMimetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 29, 2024
king rachel k.
acquired
10,002
3.00
3,334
-
Mar 29, 2024
goldberg mark alan
acquired
13,752
3.00
4,584
-
Mar 29, 2024
junius daniel m
acquired
15,627
3.00
5,209
-
Dec 29, 2023
king rachel k.
acquired
10,001
2.36
4,238
-
Dec 29, 2023
goldberg mark alan
acquired
13,751
2.36
5,827
-
Dec 29, 2023
andrews patricia s
acquired
12,250
2.36
5,191
-
Sep 30, 2023
goldberg mark alan
acquired
13,750
1.5
9,167
-
Sep 30, 2023
andrews patricia s
acquired
12,250
1.5
8,167
-
Sep 30, 2023
king rachel k.
acquired
10,000
1.5
6,667
-
Sep 22, 2023
rock edwin
bought
41,956
1.38
30,403
chief medical officer

1–10 of 50

Which funds bought or sold GLYC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-81,000
-
-%
May 17, 2024
Artal Group S.A.
unchanged
-
5,497,190
25,767,200
0.66%
May 16, 2024
JANE STREET GROUP, LLC
added
406
732,968
867,825
-%
May 15, 2024
683 Capital Management, LLC
sold off
-100
-45,746
-
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
reduced
-82.29
-302,444
87,900
-%
May 15, 2024
NEA Management Company, LLC
reduced
-19.51
261,038
11,505,100
0.71%
May 15, 2024
Brevan Howard Capital Management LP
new
-
70,017
70,017
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
719
64,064
70,866
-%
May 15, 2024
LMR Partners LLP
new
-
42,306
42,306
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
149,394
149,394
-%

1–10 of 41

Are Funds Buying or Selling GLYC?

Are funds buying GLYC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GLYC
No. of Funds

Unveiling GlycoMimetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 08, 2024
new enterprise associates 10 l p
-
0
SC 13D/A
Feb 29, 2024
new enterprise associates 10 l p
6.2%
4,007,977
SC 13D/A
Feb 12, 2024
new enterprise associates 10 l p
7.3%
4,721,876
SC 13D/A
Feb 09, 2024
artal international s.c.a.
13.3%
8,589,064
SC 13G/A
Jan 29, 2024
biotechnology value fund l p
7.7%
4,980,812
SC 13G/A
Feb 13, 2023
artal international s.c.a.
12.5%
6,573,798
SC 13G
Feb 10, 2023
new enterprise associates 10 l p
9.5%
4,967,530
SC 13D/A
Jul 12, 2021
blackrock inc.
1.7%
886,148
SC 13G/A
Feb 16, 2021
camber capital management lp
4.60%
2,013
SC 13G/A
Feb 12, 2021
ecor1 capital, llc
0%
0
SC 13G/A

Recent SEC filings of GlycoMimetics Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 08, 2024
SC 13D/A
13D - Major Acquisition
May 06, 2024
8-K
Current Report
May 02, 2024
8-K
Current Report
May 01, 2024
4
Insider Trading
May 01, 2024
4
Insider Trading
May 01, 2024
4
Insider Trading
May 01, 2024
4
Insider Trading
May 01, 2024
4
Insider Trading

Peers (Alternatives to GlycoMimetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
17.55% 15.42%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
6.10% -19.49%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.03% -10.77%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
4.06% -3.24%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
16.82% -26.89%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
20.98% 97.26%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
19.55% 492.49%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-16.55% 51.92%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

GlycoMimetics Inc News

Latest updates
Yahoo Movies UK10 Jun 202410:21 am
Seeking Alpha09 May 202407:00 am
InvestorPlace06 May 202407:00 am
Seeking Alpha30 Apr 202407:00 am

GlycoMimetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42022Q42022Q32022Q22021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12015Q42015Q32015Q22014Q42014Q32014Q22014Q22013Q42013Q3
Revenue----75.0018.0087.00141*1,0551631,000-9,00035.00-20,035--15,0277,55277.0053.00
Operating Expenses-9.6%9,60110,6238,76713,42817,44317,42414,40515,33515,73114,72714,10617,108---------
  S&GA Expenses-8.9%4,3124,7323,8455,4554,5484,1424,2374,1884,0114,0584,2354,440---------
  R&D Expenses-10.2%5,2885,8914,9237,97312,89513,28210,16711,14711,72010,6709,87112,668---------
EBITDA Margin815.9%474.88*51.85*26.89*26.98*4.19*3.73*2.19*2.19*-------------
Income Taxes----------------80.00-76.7677.00---
Earnings Before Taxes---------------7,16810,389--6,6948,068---3,700
EBT Margin826.2%459.55*49.61*25.65*25.63*3.96*3.52*2.07*2.07*-------------
Net Income11.4%-9,078-10,244-8,523-13,267-17,421-17,332-14,399-14,274-15,562-13,722-14,079-7,662---------
Net Income Margin-632.0%-3.69-504.06*-300.62*-349.50*-54.69*-47.18*-26.12*-25.98*-------------
Free Cashflow3.5%-7,635-7,911-8,619-16,271-12,809-16,950-13,616-14,128-------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-24.5%34.0045.0053.0062.0069.0052.0056.0065.0081.0094.00108124138143150158162168180192204
  Current Assets-24.0%33.0044.0052.0060.0068.0051.0054.0061.0077.0091.00104120134138146153157163175186198
    Cash Equivalents-25.1%31.0042.0049.0058.0065.0048.0052.0060.0077.0090.00102119132137143150155158171184196
  Net PPE---0.000.000.000.000.000.000.000.000.000.001.001.001.001.001.001.001.001.001.00
Liabilities-23.3%5.007.007.007.007.009.008.009.0013.0013.0011.0012.0013.0015.0012.0013.0014.0014.0013.0014.0012.00
  Current Liabilities-22.5%5.007.006.007.007.009.008.009.0013.0012.0010.0010.0011.0012.0010.0010.0011.0011.0010.0011.008.00
Shareholder's Equity-24.7%29.0038.0047.0055.0062.0043.0048.0056.0068.0082.0097.00112125128138146148154167179193
  Retained Earnings-2.4%-467-456-447-438-429-419-409-400-387-372-355-338-323-309-293-280-266-258-243-230-214
  Additional Paid-In Capital0.2%496495494493492462457456456454452450449438432426415413411409407
Shares Outstanding0.1%64.0064.0064.0064.0060.0054.0052.0052.0052.0051.0051.0051.0051.00--------
Float----109---31.00---118---138---400-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-37.6%-10,508-7,635-8,683-6,974-11,606-7,911-8,617-16,230-13,698-12,806-16,946-13,611-14,125-9,686-11,503-14,551-3,500-12,792-13,448-11,394-14,347
  Share Based Compensation31.2%1,1929088888588708999149641,0811,3201,5911,5621,6141,6281,6901,7621,8221,7261,5871,5191,382
Cashflow From Investing-828.7%-7.44-801*-7.87-10.53-2.20-1*-2.48-41.19-40.52-2.45-4.33-5.10-3.06-38.17-15.81-6.38-8.14-12.36-18.27-74.77-39.54
Cashflow From Financing390.3%5.00999*62.0020.0028,741----1,14021.00-9,5643,8894,5459,58013012018776.0031.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

GLYC Income Statement

2024-03-31
Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Costs and expenses:  
Research and development expense$ 6,025,461$ 5,418,706
General and administrative expense5,089,5665,522,312
Total costs and expenses11,115,02710,941,018
Loss from operations(11,115,027)(10,941,018)
Interest income378,360581,668
Net loss and comprehensive loss$ (10,736,667)$ (10,359,350)
Basic net loss per common share (in dollars per share)$ (0.17)$ (0.17)
Diluted net loss per common share (in dollars per share)$ (0.17)$ (0.17)
Basic weighted-average number of common shares outstanding (in shares)64,457,23360,350,127
Diluted weighted-average number of common shares outstanding (in shares)64,457,23360,350,127

GLYC Balance Sheet

2024-03-31
Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 31,281,460$ 41,792,830
Prepaid expenses and other current assets1,985,9331,997,904
Total current assets33,267,39343,790,734
Prepaid research and development expenses192,268603,737
Operating lease right-of-use asset598,257767,828
Other assets146,995154,176
Total assets34,204,91345,316,475
Current liabilities:  
Accounts payable755,534868,115
Accrued expenses3,907,8405,225,557
Lease liabilities630,827741,558
Total current liabilities5,294,2016,835,230
Lease liabilities, net of current portion 66,844
Total liabilities5,294,2016,902,074
Stockholders' equity:  
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock; $0.001 par value; 100,000,000 shares authorized; 64,393,744 shares issued and outstanding at December 31, 2023; 54,377,798 shares issued and outstanding at December 31, 202264,45164,394
Additional paid-in capital496,068,140494,835,219
Accumulated deficit(467,221,879)(456,485,212)
Total stockholders' equity28,910,71238,414,401
Total liabilities and stockholders' equity$ 34,204,913$ 45,316,475
GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEglycomimetics.com
 INDUSTRYBiotechnology
 EMPLOYEES38

GlycoMimetics Inc Frequently Asked Questions


What is the ticker symbol for GlycoMimetics Inc? What does GLYC stand for in stocks?

GLYC is the stock ticker symbol of GlycoMimetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GlycoMimetics Inc (GLYC)?

As of Wed Jun 12 2024, market cap of GlycoMimetics Inc is 16.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLYC stock?

You can check GLYC's fair value in chart for subscribers.

What is the fair value of GLYC stock?

You can check GLYC's fair value in chart for subscribers. The fair value of GlycoMimetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GlycoMimetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLYC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GlycoMimetics Inc a good stock to buy?

The fair value guage provides a quick view whether GLYC is over valued or under valued. Whether GlycoMimetics Inc is cheap or expensive depends on the assumptions which impact GlycoMimetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLYC.

What is GlycoMimetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, GLYC's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 1.68 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLYC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GlycoMimetics Inc's stock?

In the past 10 years, GlycoMimetics Inc has provided -0.271 (multiply by 100 for percentage) rate of return.